Advanced Search

Journal of Traditional Chinese Medicine ›› 2018, Vol. 38 ›› Issue (06): 823-833.

Previous Articles     Next Articles

A model for anticancer surveillance was pharmacologically developed to evaluate vitality principle in breast cancer rats

Liu Jinyu, Zhang Mengyang, Zhao Xin, Ge Shasha, Li Shuang, Peng Lin, Mu Yuxue, Chen Chen, Li Xiaoya, Zhang Rui, Feng Xuanye, Deng Bo, Jia Liqun, Lin Yulin, Wang Yueqi, Cheng Zhiqiang, TaeHoo Yi, Cai Dayong   

  1. Research Center for Pharmcology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College;College of Life Sciences,Kyung Hee University;College of Basic Medicine, Beijing University of Chinese Medicine;Oncology Department of Chinese Medicine, China-Japan Friendship Hospital;
  • Online:2018-12-15 Published:2018-12-15
  • Supported by:
    Supported by the National Natural Science Foundation of China"Via regulating ghrelin axis,Fuzi Lizhong pill effects on chronic atrophic gastritis with Spleen-Yang deficiency","Pharmacological mechanism of Yiqi-huoxue prescription on portal hypertension from inhibiting the oxidase hyperactivity of macrophages in portal triads"(No.81541082,81673674), the Beijing Natural Science Foundation"A pharmcodynamic model of systems biology for the joint actions of molecules from prescriptions with medical plants on portal hypertension"(No.7132150)

PDF

64

Abstract: OBJECTIVE: To evaluate vitality principle in breast cancer rats by pharmacologically developing a model for anticancer surveillance.METHODS: The breast cancer in rats was replicated with 7,12-Dimethylbenz[a]anthracene(DMBA, i.g.,100 mg/kg) at d_(001). The anticancer surveillance was defined as the intervals between the primary sensitization and the first challenge stirred with complete Freund's adjuvant(CFA), the various intervals(k = 0.80) were dominated from d_(025)(600.00 h) to d_(095)(2288.82 h). The optimal surveillant status was confirmed with the median effective interval(EI_(50))from tumor volume regressive curve, for developing the pharmacodynamic model. The tumor and tumor infiltrating lymphocyte histopathology was used to confirm the immune surveillance being affected with CFA in breast cancer tumorigenesis.The availability of this model was confirmed with Shugan Liangxue prescription(SLP), from the vitality principle, and assured further from interleukin-12 levels.RESULTS: The regressive curve was set up between the intervals and tumor volumes, the EI_(50) in SLP-treated rats(1475.00 h, Y_(SLP)= 0.1026 +0.8780/[1 + 10~(27.1425-8.565x)]) was postponed, which was 1.87 multiple of the EI_(50) in CFA rats(791.40 h, y =-0.0525 + 0.9452/[1 + 10~(30.4870-10.52x)], so did prepone the curve between the intervals and the immunological biomarker, serum interleukin-12 levels, the EI_(50) in SLP-treated rats(744.90 h, Y_(SLP)=-0.0145 + 0.7455/[1 + 10~(52.09636-18.13x)]) be 0.78 multiple of the EI_(50) in CFA rats(960.10 h, Y_(CFA)= 0.2460 + 0.7270/[1 + 10~(-67.1546 +22.52x)]), this immunological action being mediated the anticancer prognosis. Tumor histology was confirmed the more tumor infiltrating lymphocytes activated in SLP rats with CFA stirred immunity than rats only received CFA.CONCLUSION: The model for anticancer surveillance was pharmacologically established as the optimal interval(791.40 h) between the primary sensitization and the first challenge stirred with complete Freund's adjuvant. This available model was confirmed with SLP, from the vitality principle, for evaluating immunological effects against breast cancer.

Key words: Breast cancer, Pharmacology, Drug screening assays,antitumor, Freund's adjuvant, Shugan Liangxue prespriction

Cite this article

Liu Jinyu, Zhang Mengyang, Zhao Xin, Ge Shasha, Li Shuang, Peng Lin, Mu Yuxue, Chen Chen, Li Xiaoya, Zhang Rui, Feng Xuanye, Deng Bo, Jia Liqun, Lin Yulin, Wang Yueqi, Cheng Zhiqiang, TaeHoo Yi, Cai Dayong. A model for anticancer surveillance was pharmacologically developed to evaluate vitality principle in breast cancer rats[J]. Journal of Traditional Chinese Medicine, 2018, 38(06): 823-833.